AYX-201

AYX-201 is an investigational **TCNP encapsulated red cell therapy** being developed by **Ayma Therapeutics** for **acute respiratory distress syndrome** including **COVID-associated ARDS**. The program uses Ayma's transcellular nanoparticle platform to encapsulate an undisclosed therapeutic payload within red blood cells, with the apparent intent of enabling sustained and potentially targeted delivery in severe acute lung injury. Publicly available pipeline information identifies the modality and target indications, but does not disclose a specific molecular target, payload composition, dosing form, route of administration, or clinical trial phase; based on the available company pipeline materials, the program appears to be in **preclinical or very early development**.

Other names

TCNP encapsulated red cell therapyred cell-encapsulated nanoparticle